Propanc Biopharma plans Phase 1b trial of PRP in advanced solid tumors for Q1 2027
PPCB•Propanc Biopharma said preclinical results showed PRP restored chemotherapy vulnerability in resistant pancreatic cancer cells. It plans a first-in-human Phase 1b trial in Australia in Q1 2027, targeting up to 50 patients with advanced solid tumors.
1. Preclinical findings
Propanc Biopharma published preclinical results showing PRP restored chemotherapy vulnerability in resistant pancreatic cancer cells and reduced cancer cell growth and invasive behavior. The company said the findings support potential sequential or combination use with RAS inhibitors.
2. Trial plans
A first-in-human Phase 1b trial is planned for Q1 2027 in Australia, targeting up to 50 patients with advanced solid tumors. PRP holds FDA orphan drug designation for pancreatic cancer.
